Fate Therapeutics Inc (NASDAQ: FATE) on Monday, plunged -6.06% from the previous trading day, before settling in for the closing price of $1.65. Within the past 52 weeks, FATE’s price has moved between $0.66 and $3.50.
During the last 5-year period, the sales drop of Healthcare Sector giant was -2.63%. The company achieved an average annual earnings per share of 28.82%. With a float of $109.59 million, this company’s outstanding shares have now reached $114.66 million.
Fate Therapeutics Inc (FATE) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Fate Therapeutics Inc is 5.08%, while institutional ownership is 70.54%. The most recent insider transaction that took place on Aug 04 ’25, was worth 9,573. In this transaction an insider of this company sold 9,037 shares at a rate of $1.06, taking the stock ownership to the 397,670 shares. Before that another transaction happened on Aug 04 ’25, when Company’s President and CEO sold 14,466 for $1.06, making the entire transaction worth $15,396. This insider now owns 334,898 shares in total.
Fate Therapeutics Inc (FATE) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.4 earnings per share (EPS) for the period topping the consensus outlook (set at -0.41) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.53% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Fate Therapeutics Inc (FATE) is currently performing well based on its current performance indicators. A quick ratio of 8.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.18 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Looking closely at Fate Therapeutics Inc (NASDAQ: FATE), its last 5-days average volume was 3.19 million, which is a jump from its year-to-date volume of 2.1 million. As of the previous 9 days, the stock’s Stochastic %D was 58.45%.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 62.14%, which indicates a significant increase from 39.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1839 in the past 14 days, which was higher than the 0.1068 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2017, while its 200-day Moving Average is $1.1683. However, in the short run, Fate Therapeutics Inc’s stock first resistance to watch stands at $1.8316. Second resistance stands at $2.1132. The third major resistance level sits at $2.2865. If the price goes on to break the first support level at $1.3767, it is likely to go to the next support level at $1.2034. Should the price break the second support level, the third support level stands at $0.9218.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
Market capitalization of the company is 178.76 million based on 115,330K outstanding shares. Right now, sales total 13,630 K and income totals -186,260 K. The company made 1,910 K in profit during its latest quarter, and -34,070 K in sales during its previous quarter.
